A Common Signaling Cascade May Underlie "addiction" to the Src, BCR-ABL, and EGF Receptor Oncogenes

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2006 Nov 14

PMID 17097564

Citations 111

Authors

Sreenath V Sharma

Patrycja Gajowniczek

Inna P Way

Diana Y Lee

Jane Jiang

Yuki Yuza

Marie Classon

Daniel A Haber

Jeffrey Settleman

Affiliations

Soon will be listed here.

Abstract

"Oncogene addiction" describes an unexplained dependency of cancer cells on a particular cellular pathway for survival or proliferation. We report that differential attenuation rates of prosurvival and proapoptotic signals in oncogene-dependent cells contribute to cell death following oncogene inactivation. Src-, BCR-ABL-, and EGF receptor-dependent cells exhibit a similar profile of signal attenuation following oncogene inactivation characterized by rapid diminution of phospho-ERK, -Akt, and -STAT3/5, and a delayed accumulation of the proapoptotic effector phospho-p38 MAPK. These findings implicate a transient imbalance in survival and apoptotic oncogenic outputs in the apoptotic response to oncogene inactivation. Moreover, these observations implicate a common profile of signal attenuation for multiple oncogenes and suggest that "addiction" associated with apoptosis reflects an active rather than a passive process.

Citing Articles

4″-Alkyl EGCG Derivatives Induce Cytoprotective Autophagy Response by Inhibiting EGFR in Glioblastoma Cells.

Singh S, Ghosh P, Roy R, Behera A, Sahadevan R, Kar P ACS Omega. 2024; 9(2):2286-2301.

PMID: 38250397 PMC: 10795032. DOI: 10.1021/acsomega.3c06110.

Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma.

Coppieters N, Scalisi J, Digregorio M, Leparc L, Velazquez Saez L, Lombard A J Neurooncol. 2023; 161(3):515-523.

PMID: 36695974 DOI: 10.1007/s11060-023-04240-7.

An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.

Orlando E, Medo M, Bensimon A, Quintin A, Riedo R, Roth S Cell Mol Life Sci. 2022; 80(1):6.

PMID: 36494469 PMC: 9734221. DOI: 10.1007/s00018-022-04634-2.

Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1.

Jo S, Yang E, Lee Y, Jeon D, Namkung W Int J Mol Sci. 2021; 22(21).

PMID: 34769467 PMC: 8584692. DOI: 10.3390/ijms222112037.

Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells.

Shah N, Hallur P, Ganesh R, Sonpatki P, Naik D, Chandrachari K Sci Rep. 2021; 11(1):17727.

PMID: 34489494 PMC: 8421368. DOI: 10.1038/s41598-021-97059-z.

References

Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J . Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ. 2000; 7(8):685-96. DOI: 10.1038/sj.cdd.4400700. View

Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, Nishitoh H . Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J. 2001; 20(21):6028-36. PMC: 125685. DOI: 10.1093/emboj/20.21.6028. View

Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H . Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther. 2004; 3(4):465-72. View

Felsher D, Bishop J . Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999; 4(2):199-207. DOI: 10.1016/s1097-2765(00)80367-6. View

Xia Z, Dickens M, Raingeaud J, Davis R, Greenberg M . Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995; 270(5240):1326-31. DOI: 10.1126/science.270.5240.1326. View

Maroney A, Qureshi S, Foster D, Brugge J . Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells. Oncogene. 1992; 7(6):1207-14. View

Chin L, Tam A, POMERANTZ J, Wong M, Holash J, Bardeesy N . Essential role for oncogenic Ras in tumour maintenance. Nature. 1999; 400(6743):468-72. DOI: 10.1038/22788. View

ODwyer M, Mauro M, Druker B . STI571 as a targeted therapy for CML. Cancer Invest. 2003; 21(3):429-38. DOI: 10.1081/cnv-120018235. View

Sharma S, Fischbach M, Haber D, Settleman J . "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006; 12(14 Pt 2):4392s-4395s. DOI: 10.1158/1078-0432.CCR-06-0096. View

10.

Blake R, Broome M, Liu X, Wu J, Gishizky M, Sun L . SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000; 20(23):9018-27. PMC: 86555. DOI: 10.1128/MCB.20.23.9018-9027.2000. View

11.

Klucher K, Lopez D, Daley G . Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998; 91(10):3927-34. View

12.

Huettner C, Zhang P, Van Etten R, Tenen D . Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 1999; 24(1):57-60. DOI: 10.1038/71691. View

13.

Mukohara T, Engelman J, Hanna N, Yeap B, Kobayashi S, Lindeman N . Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005; 97(16):1185-94. DOI: 10.1093/jnci/dji238. View

14.

Brunet C, Gunby R, Benson R, Hickman J, Watson A, Brady G . Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Differ. 1999; 5(1):107-15. DOI: 10.1038/sj.cdd.4400334. View

15.

Jiang J, Greulich H, Janne P, Sellers W, Meyerson M, Griffin J . Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005; 65(19):8968-74. DOI: 10.1158/0008-5472.CAN-05-1829. View

16.

Bandyopadhyay G, Biswas T, Roy K, Mandal S, Mandal C, Pal B . Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood. 2004; 104(8):2514-22. DOI: 10.1182/blood-2003-11-4065. View

17.

Arber N . Janus faces of ras: anti or pro-apoptotic?. Apoptosis. 2003; 4(5):383-8. DOI: 10.1023/a:1009651406017. View

18.

Vos M, Martinez A, Ellis C, Vallecorsa T, Clark G . The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem. 2003; 278(24):21938-43. DOI: 10.1074/jbc.M211019200. View

19.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

20.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View